Aclarion (NASDAQ:ACON) Director Buys $15,989.61 in Stock

Aclarion, Inc. (NASDAQ:ACON) Director Amanda Williams purchased 5,857 shares of the stock in a transaction on Monday, August 17th. The shares were acquired at an average cost of $2.73 per share, for a total transaction of $15,989.61. Following the transaction, the director owned 25,857 shares of the company’s stock, valued at approximately $70,589.61. The trade was a 29.28% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Aclarion Stock Up 0.7%

NASDAQ:ACON opened at $2.71 on Friday. Aclarion, Inc. has a 12-month low of $1.95 and a 12-month high of $12.03. The firm has a market capitalization of $7.81 million, a price-to-earnings ratio of -0.37 and a beta of 1.21. The stock’s 50 day moving average price is $2.66 and its two-hundred day moving average price is $2.97.

Aclarion (NASDAQ:ACON) last issued its earnings results on Thursday, August 6th. The company reported ($1.12) EPS for the quarter, missing the consensus estimate of ($1.05) by ($0.07). The business had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.03 million. Aclarion had a negative return on equity of 59.34% and a negative net margin of 10,948.81%. Equities research analysts expect that Aclarion, Inc. will post -4.51 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have commented on ACON. Wall Street Zen raised shares of Aclarion from a “sell” rating to a “hold” rating in a research report on Saturday, June 20th. Ascendiant Capital Markets upped their price objective on shares of Aclarion from $7.00 to $7.50 and gave the company a “buy” rating in a report on Friday, May 29th. Finally, Weiss Ratings raised shares of Aclarion from a “sell (e)” rating to a “sell (e+)” rating in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $7.50.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.